With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...
As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...
State DHS officials say new weight-loss drugs are driving up costs for Pennsylvania’s Medicaid program, likely leading to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback